[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615640":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":30,"studyPopulation":31,"armGroups":32,"interventions":26,"overallOfficials":35,"centralContacts":40,"locations":45,"responsibleParty":69,"collaborators":26,"id":72,"slug":26,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":85,"studyType":86,"phases":26,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Ukrainian Society of Clinical Oncology","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Mortality rate","Mortality rate associated with endoscopic vacuum therapy","90 days after last endo-vac placement",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"Morbidity rate","Rate of complications associated with endoscopic vacuum therapy or ineffective local control","90 days after last endoscopic vacuum placement",{"measure":19,"description":20,"timeFrame":21},"Time from AL diagnosis to discharge","time from AL diagnosis to discharge","The number of days from from AL diagnosis to discharge",{"measure":23,"description":24,"timeFrame":25},"Patients satisfactory rate","Patients satisfactory rate assessed by quality of life questionnaires and patient-reported outcomes scales","90 days after discharge, 365 days after discharge, 2\u002F3\u002F4\u002F5 years after discharge",null,{"allocation":26,"interventionModel":26,"interventionModelDescription":26,"primaryPurpose":26,"observationalModel":28,"timePerspective":29,"maskingInfo":26},"COHORT","PROSPECTIVE","Patients who are diagnosed with asophago-jejunal anastomotic leakage will undergo endoscopic vacuum therapy. Local source control may be additionally achieved with para-anastomotic drains.","Study population involves ukrainian patients who developed esophago-jejunal anastomotic leak after total gastrectomy due to gastric cancer",[33],{"label":34,"type":26,"description":30,"interventionNames":26},"Endo-vac cohort",[36],{"name":37,"affiliation":38,"role":39},"Oleksii Dobrzhanskyi, MD","National Cancer Institute (NCI)","PRINCIPAL_INVESTIGATOR",[41],{"name":37,"role":42,"phone":43,"phoneExt":26,"email":44},"CONTACT","+380638760185","alekseydobrzhanskiy@gmail.com",[46],{"facility":47,"status":48,"city":49,"state":26,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"National Cancer Institute","RECRUITING","Kyiv","03022","Ukraine","UA",{"type":54,"coordinates":55},"Point",[56,57],30.5238,50.45466,{"lat":57,"lon":56},[60,62,65,67],{"name":61,"role":42,"phone":43,"phoneExt":26,"email":44},"Oleksii Dobrzhanskyi",{"name":63,"role":64,"phone":26,"phoneExt":26,"email":26},"Yurii Kondratskyi, MD, PhD","SUB_INVESTIGATOR",{"name":66,"role":64,"phone":26,"phoneExt":26,"email":26},"Mykyta Pepenin, MD",{"name":68,"role":64,"phone":26,"phoneExt":26,"email":26},"Andrii Horodetskyi, MD",{"type":39,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Oleksii Dobrzhanskiy","Surgical oncoligist","100615640",false,"NCT07295236","Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak","Prospective Observational Study on Endo-vac Therapy for Esophago-jejunal Anastomotic Leak","ENDO-VAL","Inclusion Criteria:\n\n* patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis\n* patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery\n\nExclusion Criteria:\n\n* unstable patients who developed esophago-jejunal anastomotic leak\n* patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference\n* patients who rejected endoscopic vacuum therapy","ALL","18 Years","90 Years",{"count":83,"type":84},100,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to assess the impact of endoscopic vacuum therapy in patients who underwent total gastrectomy due to gastric cancer and developed esophago-jejunal anastomotic leakage. The main outcomes to be investigated are the following:\n\nPrimary endpoint: mortality rate Secondary endpoints: morbidity rate, time from AL diagnosis to discharge, patients satisfactory rate.",[89],"Esophagojejunal Anastomotic Leak",[91,92,93,94],"gastric cancer","esophagojejunal anastomotic leak","total gastrectomy","Endoscopic vacuum therapy","2025-12-21",{"date":97,"type":98},"2025-12-29","ACTUAL",{"date":100,"type":98},"2025-12-01",{"date":102,"type":84},"2035-12-01",{"name":5,"class":6},1]